Advancements in Bladder Cancer Treatment Revolutionize Standard of Care
TL;DR
The combination of Seagen and Astellas Pharma's Padcev with Merck's Keytruda has been hailed as the "new standard of care" in first-line bladder cancer, according to confirmatory trial data presented at the European Society for Medical Oncology (ESMO) conference. The combination therapy demonstrated significantly improved overall survival and progression-free survival compared to chemotherapy, potentially expanding the eligible patient population.
- Padcev-Keytruda sets new standard in bladder cancer as Seagen and Astellas move toward full approval: #ESMO23 Endpoints News
- New ways to treat bladder cancer improve survival and shake up the standard of care, new studies show CNN
- Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO BioSpace
- Merck Stock: How A New Combo Could 'Rewrite Textbooks' In Bladder Cancer Treatment Investor's Business Daily
- Bladder Cancer Treatment: Merck, Seagen Drug Cocktail Set to Replace Chemo Bloomberg
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News